论文部分内容阅读
目的：探讨增强ＬＡＫ细胞抗肿瘤作用的新方法．方法：用健康人外周血经密度梯度离心法分离出单个核细胞，再加入白细胞介素２（ＩＬ－２）后诱导的ＬＡＫ细胞为效应细胞，采用４－ｈ￣５１Ｃｒ释放法检测了其对胃癌细胞ＫＡＴＯⅢ的杀伤作用及加入抗胃癌单克隆抗体ＭＧｂ２后的影响．结果：发现利用单抗ＭＧｂ２和ＬＡＫ细胞产生的抗体依赖细胞介导的细胞毒性作用（ＡＤＣＣ）可以明显增强ＬＡＫ细胞的抗胃癌作用（约１００％，Ｐ＜０．０１）．此作用在单克隆抗体浓度为０．０１ｍｇ／Ｌ时出现，２ｍｇ／Ｌ时达到高峰．制备ＬＡＫ细胞时ＩＬ－２的浓度，不仅影响ＬＡＫ活性，也影响着相应的ＡＤＣＣ效应．结论：利用单抗ＭＧｂ２和ＬＡＫ细胞产生的ＡＤＣＣ效应可以明显增强ＬＡＫ细胞的抗胃癌作用．
Objective: To explore a new method to enhance the anti-tumor effect of LAK cells. METHODS: Peripheral blood from healthy volunteers was used to separate mononuclear cells by density gradient centrifugation. LAK cells induced by interleukin 2 (IL-2) were used as effector cells and detected by 4-h ̄51Cr release method. The killing effect of KATOIII in gastric cancer cells and the effect of anti-gastric cancer monoclonal antibody MGb2. RESULTS: It was found that the antibody-dependent cell cytotoxicity (ADCC) produced by the monoclonal antibodies MGb2 and LAK cells can significantly enhance the anti-gastric cancer effect of LAK cells (approximately 100%, P<0.01). This effect appeared when the concentration of monoclonal antibody was 0.01mg/L, peaked at 2mg/L. The concentration of IL-2 in the preparation of LAK cells not only affects LAK activity, but also affects the corresponding ADCC effect. Conclusion: The ADCC effect produced by monoclonal antibodies MGb2 and LAK cells can significantly enhance the anti-gastric cancer effect of LAK cells.